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The Clinical Implications for
Spectrum of HIV Public Policy
Infections:
Kenneth H. Mayer, M.D.
The term acquired immunodeficiency syndrome (AIDS) is a definition developed by the
Centersfor Disease Control to explain the epidemic ofimmunosuppression first seen in
the United States among gay and bisexual men and intravenous drug users in the early
1980s. It is now known that the human immunodeficiency virus (HIV) is the necessary
agentfor the compromise ofthe immune system which results in AIDS; however, there is a
wide range ofmanifestations associated with HIV infection. Individuals with AIDS tend to
have severe opportunistic infections or malignancies, and the vast majority ofindividuals
die within two years after the diagnosis. At least afourth ofthe individuals with HIV infec-
tion in one study werefound to remain asymptomatic after seven years ofinfection. Be-
tween the long period ofasymptomatic infection and the development oflife-threatening
opportunistic infections, individuals may develop subacute manifestations ofHIV infec-
tion. Some individuals may develop constitutional symptoms, without any other medical
explanation. The clinical use oftests ofimmunologicfunction as well as newer tests that
may describe the type ofHIV infection, such as the serum antigen test, may enhance the
ability ofclinicians to give infectedpatients more specific information as to theirprogno-
sis. As newer therapies are developed, the utilization ofnewer diagnostic tests may allow
for staging more rational treatmentplans. The data suggesting increasing efficacy of
Azidothymidine (AZT), as well as the development ofnewer chemotherapeutic agents, may
lead to more widespread HIV testing in order to detect infection at early stages and inter-
vene with specific therapies. Use ofthe test as a means ofaltering behavior remains con-
troversial. The development ofnewer therapies is hindered by the need to avoid exposing
HIV-infected individuals to agents that subsequently turn out to be harmful, such as HPA-
23 and Suramin. But this must be balanced with the urgent need ofindividuals to tryprom-
ising therapeutic agents. Preliminary data suggest that individuals who are treated with
AZTat earlier stages ofHIV infection may do better; thus, there may be a move in the
future to treatpeople with AZT. The clinical dilemma willpersistfor some time to come,
and the cost ofcarefor individuals with AIDS and HIV infection will be extremely high.
Although the illness isfrequentlyfatal, it is most appropriate to be considerate of
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37
New England Journal ofPublic Policy
the individual 's desire to have more aggressive therapies, given the variability ofHIV
infectionfor each person and thefact that new therapeutic breakthroughs are being made
every day.
The AIDS epidemic is profoundly affecting the general public regarding issues of
social policy, ranging from the sexual counter-revolution to how one deals with
primeval fears of contagion in the age of instant global transport. Medical clinicians com-
prise one of the groups that have had to respond most to the multiple conundra associated
with this epidemic. They were also among those individuals who initially recognized that
something new was occurring with the disease in the early 1980s. Nosology is that branch
of medical science which deals with the classification of diseases, and at the outset of
what is now perceived as a global problem, the new epidemic was a clinically complicated
nosological question. Young males, predominantly gay men with multiple sexual part-
ners, as well as a few intravenous drug users, in a discrete number of cities — that is, New
York City, San Francisco, and Los Angeles — were perceived to be developing illnesses
associated with deranged immunoregulation. The first published report in the medical
literature regarding what is now known as the AIDS epidemic was in the Morbidity and
Mortality Weekly Report , a newsletter of the Centers for Disease Control (CDC), which
described several cases of Pneumocystis carinii pneumonia in Los Angeles. 1 The authors
noted that all of the infected individuals were exposed to cytomegalovirus and wondered
whether this virus could be playing a role that could explain why homosexually active
males were developing a disease previously associated with individuals who were iatro-
genically immunocompromised or malnourished. The subsequent reports of Kaposi's
sarcoma, 2 which may occur in immunocompromised individuals, and the appearance of
Pneumocystis carinii in individuals who presumably could have been infected via contam-
inated needles, helped to buttress the possibility that a specific infectious agent that could
be transmitted sexually and via blood was resulting in the epidemic of immunosuppres-
sion. However, for several years an ongoing debate raged, with at least three sides. Some
felt that this epidemic was due to a new infectious agent; some thought it was due to agents
already present which might have undergone evolution (such as cytomegalovirus, or a
combination of infectious agents); and others felt that the epidemic represented a burnout
of the immune system, because high-risk individuals tended to be exposed to multiple
agents, drugs, and other nonspecific antigens that tended to overwhelm their host de-
fenses. Subsequent elucidation of the retroviral etiology of HIV infection, 3 4 which was
abetted by careful epidemiological studies linking new risk groups and helping to develop
a very tight case that HIV was the etiologic agent, 5 has not necessarily diminished the
diagnostic and therapeutic questions facing clinicians today. More than six years into the
epidemic, clinicians still cannot accurately tell individuals who are infected with HIV
when and whether they will develop AIDS and whether they should take Azidothymidine
(AZT) or one of the other, less studied treatment regimens.
Definition of the Clinical Spectrum of the Epidemic
When the epidemic of immunodeficiency was first recognized in the early 1980s, the
Centers for Disease Control was given the responsibility of trying to define a process
whose origin was unclear, whose etiology was unknown, and whose natural history was
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uncharted. Fortunately, the revolution in immunologic understanding and diagnostic
techniques which had occurred in the late 1970s allowed for the conceptualization that a
major cell that regulated many aspects of host immune response, the T-helper lymphocyte,
was numerically depleted and functionally impaired. All the individuals with this type of
impairment manifested one or another of an increasing number of atypical infections and
neoplasms. 6 The aggregation of a specific type of immunologic impairment, specific
distinctive and atypical types of illnesses, in individuals with specific risk behaviors,
allowed the Centers for Disease Control to evolve a case definition of what came to be
known as the acquired immunodeficiency syndrome. The dilemma that these investigators
faced was how to define this process that was still so unclear without lumping into it indi-
viduals whose infections or neoplasms, or both, were due to other causes while at the
same time not leaving out the increasing numbers of individuals with some evidence of T-
helper lymphocyte immunologic impairment. At an early point in time, the CDC decided
to take a narrow-based approach in which cases reported which related to the epidemic
would be those of the sickest individuals who did not have other reasons for immunosu-
pression but who had one of a specific laundry list of clinical syndromes that were distinc-
tively atypical in individuals whose immune systems were intact. 7 This approach was
extremely effective in picking up individuals who had the classic signs of immunologic
impairment and conditions which were the most commonly seen in the course of the epi-
demic, such as Pneumocystis carinii pneumonia and Kaposi's sarcoma. Neither of these
conditions occurred with any significant frequency in individuals who were not immuno-
suppressed or elderly, or both.
However, other individuals developed illnesses that were not specific to immunocom-
promised individuals, but the severity of their manifestations suggested that they were
immunologically impaired. For example, herpes simplex infection around the mouth or
Table 1
Summary of Centers for Disease Control (CDC)
Classification System for HIV Infections
Group I. Acute infection
Group II. Asymptomatic infection*
Group III. Persistent generalized lymphadenopathy
Group IV. Other disease
Subgroup A. Constitutional disease
Subgroup 6. Neurological disease
Subgroup C. Secondary infectious diseases
Category C-1 . Specified secondary infectious diseases
listed in the CDC surveillance definition for AIDS*
Category C-2. Other specified secondary infectious diseases
Subgroup D. Secondary cancers*
Subgroup E. Other conditions
*Patients in groups II and III may be subclassified on the basis of a laboratory evaluation.
includes those patients whose clinical presentation fulfills the definition of AIDS
used by the CDC for national reporting.
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the perirectal area is not an uncommon infection of homosexually active males who have
multiple partners, but the persistence of perianal ulcerations around the rectum in the
setting of immunologic abnormalities seen in blood tests was highly suggestive of the
wider spectrum of the epidemic. Even more difficult for the clinician were individuals
who had persistent wasting syndromes accompanied by significant weight losses, persis-
tent fevers, and malaise, who despite extensive medical evaluations did not have specific
infectious agents always identified as the source of their problems. Other individuals who
are at high risk to develop AIDS continue to be well for long periods of time with asymp-
tomatic immunologic abnormalities, or may show evidence only of persistent generalized
lymph gland swelling associated with blood test abnormalities. 8 9 Astute clinicians in the
cities where the epidemic was first appreciated noted that individuals often progressed
from asymptomatic conditions to those of lesser severity to the more severe opportunistic
infections. Others noted that certain processes were more common in individuals with
specific risk characteristics; for example, homosexually active males were more likely to
have Kaposi's sarcoma than individuals who were intravenous drug users. 10
Even before HIV was delineated as the etiologic agent, clinicians and epidemiologists
expanded their vision of the epidemic to incorporate the concept of the iceberg, with those
conditions defined as AIDS representing the tip of the iceberg. Progression from asymp-
tomatic high-risk status to full-blown opportunistic infections helped to develop this con-
cept. Even more convincing was the delineation of the similar spectrum of degrees of
immunocompromise among individuals who had received blood transfusions from indi-
viduals who had subsequently developed AIDS, and among individuals from other nations
who did not have any history of homosexual activity or intravenous drug use. The devel-
opment of an intellectual model of a process that resulted in immunocompromise, with
opportunistic infections and neoplasms subsequently supervening, was validated once
HIV was isolated, and appropriate seroepidemiologic studies were undertaken which
confirmed the increased prevalence of this virus in individuals with AIDS and related
symptom complexes.
One might ask, Why should the arbitrary definition ofAIDS continue to be reported
when one can actually monitor the prevalence of the causative agent itself? Although
infection with HIV is necessary for an individual to develop AIDS, it is still not clear
whether all individuals who are HIV-infected will ultimately develop the full-blown syn-
drome. The best data that bear on this issue are derived from a hepatitis B vaccine study
that took place in San Francisco from 1978 to 1980 at a clinic for sexually transmitted
diseases which is run by the city health department. Of the gay and bisexual men who
were found to be infected with HIV between 1978 and 1980, more than one-third devel-
oped CDC-defined AIDS by 1987, and approximately 25 percent remain completely
asymptomatic. 11 The range for individuals in the middle zone includes asymptomatic
immunologic abnormalities; persistent generalized lymphadenopathy; minor opportu-
nistic infections such as thrush and zoster; and the presence of persistent constitutional
symptoms. We must be careful about generalizing from this cohort, since prior to recog-
nition of the AIDS epidemic in the early 1980s, there was no widespread education as to
what constituted safer sexual practices. If repeated exposures to HIV or other sexually
transmitted viruses such as cytomegalovirus and Epstein-Barr virus result in synergistic
immunosuppression with the initial HIV infection, then the rates of progression from
asymptomatic HIV infection from the men in this cohort could represent a worst-case
scenario. However, no single study of homosexual or heterosexual exposure has indicated
that unsafe sex after initial HIV infection results in more rapid immunocompromise, and
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thus the data generated from this cohort can be utilized as a point of reference despite
such sexual practices.
The finding that a substantial number of individuals who are HIV-infected develop full-
blown AIDS does not mean that a separation in reporting of AIDS is not useful at the
present time. Individuals who do not have AIDS may need to utilize many health care
services, including multiple laboratory tests, medical evaluations of recurrent minor
opportunistic infections, and counseling and support services. Individuals with AIDS
tend to have much more severe medical illnesses; thus, monitoring the increasing number
of individuals who frequently require intensive, tertiary services is a useful way to moni-
tor health care utilization and to assist planners in projecting what types of resources it
will be necessary to deploy as the epidemic continues to progress. AZT is the first drug
that has been shown to assist in extending life in individuals with AIDS or with the ill-
defined AIDS-related complex (ARC), a term that usually relates to constitutional symp-
toms associated with HIV infection. It is not known at the present time whether AZT will
ultimately forestall the progression to AIDS of many individuals whose HIV infection is
rapidly progressing. ("Ill-defined" is used here as a descriptor because specialists do not
agree on the definition of AIDS, and therefore various articles and other writings refer to
different levels of morbidity.) If current projections by the Centers for Disease Control
are correct, between 1 million and 1.5 million Americans are currently infected with
HIV, and by 1991 more than a quarter million of them will have developed CDC-defined
infections or neoplasms that are now described as one of the conditions defined as AIDS. 12
The Wide Spectrum ofHIV Infection
Intimate sexual contact with an HIV-infected partner or the sharing of contaminated nee-
dles does not invariably result in HIV infection. In a prospective study of homosexually
active male partners conducted in Boston, more than one-third of the partners were dis-
cordant (that is, one partner was seronegative and the other, seropositive) despite possible
high-risk anal exposures to infected ejaculate on the part of the susceptible seronegative
partner.
,3 Whether certain individuals are intrinsically more able to resist infection with
HIV or whether some infected individuals are less capable of transmission is not clear at
the present time. Some lines of data suggest that individuals may become more efficient
in the transmission of HIV infection the longer they carry the virus. This observation has
been made concerning hemophiliacs and their spouses; 14 concerning homosexually active
male partners; in the recipients of infected blood; 15 and in perinatal studies. 16
Once an individual has become infected with HTV, it most often takes between three and
twelve weeks to develop detectable antibodies. The vast majority of individuals have de-
tectable markers for HIV infection by six months, although there are rare individuals who
have not developed HIV antibodies after several years of follow-up. Newer diagnostic
tests, such as the detection of serum antigen, may permit demonstration that an HTV expo-
sure has occurred prior to the development of antibody. At the time of seroconversion,
individuals may manifest a number of symptoms, including a mononucleosis-type syn-
drome; rashes that may be hivelike or maculopapular; an aseptic meningitis; and unex-
plained fevers. 17 18 However, many individuals, perhaps most, may remain completely
asymptomatic for several years after becoming HIV-infected. In response to the increas-
ing understanding of the wide spectrum of HIV infection, the CDC has developed a
classification system (see table 1) which describes individuals with acute infection,
asymptomatic infection, and persistent generalized lymphadenopathy, as well as those
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who have clinically significant HIV infection, that is, opportunistic neoplasms and infec-
tions, neurological syndromes, or constitutional symptoms, or a combination of these. 19
The individuals in the first three groups of the CDC classification system have highly
variable courses. For example, some persons may have persistent HIV-related lymph-
adenopathy for many years without any other subsequent untoward sequelae. 20 However,
once individuals develop systemic complaints and constitutional symptoms, there may be
a rapid progression to more severe complications of HIV infection which are subsumed
under the acronym AIDS (see tables 2 and 3).
Individuals who have early HIV infection present difficult decisions for clinicians
regarding questions of appropriate interventions to prevent them from further immuno-
compromise. Several studies are now under way in the AIDS Treatment Evaluation Units
(ATEUs) that are funded by the National Institutes of Health (NIH). These studies will
attempt to determine whether asymptomatic seropositive individuals will benefit from
receiving AZT. However, it may take several years to answer this question. In the mean-
time, many worried individuals who are aware that a subsequent clinical decline is a fre-
quent outcome of long-standing asymptomatic infection try to obtain drugs through black
markets — drugs that may be homemade, such as AL-721 , or that may be smuggled in
from Mexico, such as Ribavirin. Another dilemma for clinicians concerns the decision
about how aggressively to diagnostically evaluate individuals with generalized lymph-
adenopathy. At the early phase of the epidemic, many clinicians were more likely to do
lymph node biopsies on patients who had persistent swollen glands, even in the absence of
constitutional signs. It has subsequently emerged that without the evidence of hematologic
or clinical abnormalities, biopsy most often results in finding a lymph node whose histo-
logic pattern is termed "reactive follicular hyperplasia," a pattern that tells the health care
workers only that the lymph gland is "turned on," without conveying any specific prog-
nostic information. 21
Whether or not an individual has swollen lymph glands, the onset of so-called constitu-
tional symptoms— that is, persistent fevers, chills, sweats, weight loss, and malaise— is
generally a negative prognostic sign.
22
Obviously, individuals with HIV infection may
have any of these symptoms for other reasons, some of which may or may not portend the
onset of an opportunistic infection. Very often, HIV-positive individuals and their clini-
cians are in a state of worried anticipation once these types of symptoms supervene. An
episode of influenza can be emotionally upsetting and result in unnecessary diagnostic
studies in anxious seropositive persons. The chronicity of symptoms, generally lasting
more than a month, may be a sign that the HIV infection has resulted in a new state of
more severe immunocompromise and susceptiblity to opportunistic infection. Individuals
with constitutional symptoms generally need to have an extensive medical workup, since
some of the conditions they have may be treatable and may be more amenable to therapy
if diagnosed early. However, HIV infection itself can result in any of these symptoms,
as well as a wide range of neurological findings, though some individuals may undergo
expensive workups without obtaining a definitive answer. However, one cannot take the
attitude that if the workup initially is negative, there is no use in repeating it if further
symptoms develop. Unfortunately, once an individual undergoes a diminution in the abil-
ity of the immune system to respond to specific infectious processes, then there is a pro-
pensity for developing multiple infections, and thus each new sign or symptom has to be
evaluated independently of prior symptom complexes. This possibility for serial infec-
tions, sometimes with multiple agents, tends to make the medical management of individ-
uals with HIV infection particularly labor-intensive and costly. The clinician must always
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balance the aggressiveness of the clinical workup against appropriate therapeutic options
for individuals with the AIDS-related complex, but more often than not, it is desirable to
proceed with the latest diagnostic tests, since isolation of specific organisms or the defini-
tion of specific clinical conditions can lead to appropriate therapy and may result in an
improved quality of life for the patient.
The opportunistic infections that individuals develop with AIDS may be due to orga-
nisms that are ubiquitous in a specific environment, so that Pneumocystis carinii pneu-
monia is much more common in North America and Europe than in Africa, whereas
cryptococcal meningitis and Isospora belli enteritis are much more common there. Other
opportunistic infections represent reactivation of chronic latent viruses that may have
been acquired at earlier ages as the result of intimate contact, such as herpes simplex,
cytomegalovirus, and Epstein-Barr virus. However, in individuals with AIDS and severe
immunodeficiency due to HIV, these viruses may reactivate in particularly virulent
forms, so that chronic, persistent perianal ulcerations may be due to herpes simplex, 23 or
cytomegalovirus may result in colitis, blindness, or a refractory pneumonia, syndromes
associated with this virus which are seen only in severely debilitated hosts. 24 One conun-
drum in individuals with AIDS is that with appropriate medical technology, most of these
Table 2
Opportunistic Infections Indicative of a Defect in
Cellular Immune Function Associated with AIDS
A. Helminthic Infection





2. Disseminated toxoplasmosis, or toxoplasma encephalitis, excluding con-
genital infection
3. Chronic Cryptosporidium enteritis (> 1 month)
4. Chronic Isospora belli enteritis ( > 1 month)
C. Fungal Infection
1 Candida esophagitis, bronchopulmonary candidiasis*
2. Cryptococcal meningitis, or disseminated infection
3. Disseminated histoplasmosis*
D. Bacterial Infection
1 Disseminated (not just pulmonary or lymphatic) M. avium-intracellulare or
M. kansasii
2. Extrapulmonary tuberculosis*
E. Noncongenital Viral Infection
1 Chronic ( > 1 month) mucocutaneous herpes simplex
2. Histologically evident cytomegalovirus infection, including liver or lymph
node
3. Progressive multifocal leukencephalopathy
hNot listed in original CDC definition of AIDS but subsequently added.
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Table 3
Opportunistic Malignancies Indicative of a Defect in




Kaposi's sarcoma (in a person less than sixty years old)
2. High-grade, B-cell non-Hodgkin's lymphoma*
A. Burkitt's lymphoma
B. Undifferentiated non-Hodgkin's lymphoma, immunoblastic sarcoma
3. Primary brain lymphoma
*Not listed in original CDC definition of AIDS but subsequently added.
opportunistic infections or neoplasms can be diagnosed, and most of them can be treated.
However, the recurrent succession of these debilitating diseases is analogous to the Hydra
monster of Greek mythology, which grew back two heads for every one that was cut off. It
is this succession of diseases that causes the ultimate mortality from AIDS.
The problem for the patient, the clinician, and society at large is how to determine when
the diminishing returns of each new intervention mandate a less thorough investigation of
the cause of new complaints. Although individuals who have had their third episode of
Pneumocystis carinii pneumonia are much less likely to survive than those who have had
their first, this kind of information only gives probablistic odds, and does not address the
question for each individual of whether life extension at specific junctures promotes hu-
man dignity or human suffering.
Infection with HIV may result in neurological disease after initial seroconversion but
more often manifests itself later in the course ofHIV infection, though specific neurologi-
cal sequelae may be seen at any point in time. 25 The most dramatic findings include de-
mentia, encephalopathy, and neuropathies, which may involve either muscles or
sensation, or both, as well as involvement of the spinal cord. 26 27 Individuals with HIV
infection may be more anxious or depressed, or both, because of the knowledge of their
status and because of the social stresses attendant upon being a member of a high-risk
group and carrying a life-threatening virus, but independent of these other behavioral
modifiers, HIV infection may alter psychological and neurological functions early in the
course of the illness. Thus, health care planners must integrate the psychosocial and
neuro-behavioral needs of individuals with HIV infection in the calculations of the soci-
etal costs of infection, which have thus far been estimated to add as much as $8 billion to
$16 billion to the cost of health care in the United States by 1991
,
28
Immature immune systems appear to be even more susceptible to the ravages of HIV
infection, presumably because there are no immunologic reserves that have developed
over several decades of successfully fending off environmental challenges. 29 Although a
consensus among experts does not exist regarding the frequency with which offspring of
HIV-infected mothers will be infected themselves, there is general agreement that it is a
substantial figure, possibly the majority of live births.
30 These children may be born to
mothers who are addicted to drugs or are from disadvantaged socioeconomic environ-
ments, or both, and who have to cope with their own HIV infections with all those associ-
ated medical problems. Children born with HIV infection may encounter difficulties in
placement if their mothers and families are unable to care for them. Thus, the problem of
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pediatric AIDS, which has grown rapidly in several major metropolitan areas — particu-
larly New York, northern New Jersey, and Miami — raises additional medical, sociologi-
cal, and ethical concerns for the development of public policy.
Clinical Management Issues: Diagnostic Concerns
The first major clinical use of the HIV antibody test was for the purpose of screening
donated blood in order to protect the blood supply. 31 In the first few years of the test's
utilization, a wide-ranging public debate occurred in which some individuals were propo-
nents of using the test to screen the entire population, or subgroups of the population,
such as individuals seeking marriage licenses; health care professionals; and individuals
entering hospitals or being prepared for major surgery. Opponents of these more liberal
indications for use of the HIV antibody test pointed out that despite the test being progres-
sively improved and despite the ability to utilize independent corroboration with other
more sophisticated tests such as the Western blot, testing for antibodies still seemed to
produce an unacceptably high number of false positives, particularly in low prevalence
areas, even though the use of a corroborative test substantially reduces the number of
false positives. 32,
33 Another concern voiced by opponents of large-scale testing of the
general population was that even if all individuals identified as seropositive were truly
infected with HIV, once they were identified as seropositive there would be no effective
therapies available to offer them. They would have knowledge that they were at increased
risk for AIDS and would be at risk for many types of discrimination if the information
could not be absolutely protected, with no prospect for reversing their infection. How-
ever, over the past year, clinical studies indicate that AZT is efficacious in prolonging life
in individuals with AIDS and AIDS-related symptoms, 34 raising new questions of when to
test. At the present time, AZT has not been shown to be effective in preventing AIDS in
asymptomatic HIV-seropositive individuals, but the studies that are currently under way
to evaluate this possibility could radically alter the clinical indications for HIV antibody
screening. IfAZT or any other antiretroviral drug is shown to prevent immunocom-
promise in asymptomatic seropositives, the argument could run that proactive HIV test-
ing would be useful so that more individuals could be diagnosed and treated before the
onset of irreversible clinical disease.
The argument that the detection of early infection may help prevent subsequent spread
into the general population and may reduce morbidity has been the basis for much of
current public health policy with regard to other sexually transmitted diseases. Since at
the present time AZT looks promising but has not yet been shown to be effective for treat-
ing asymptomatic persons, there is much turmoil regarding this issue. Up to one-third of
persons with AIDS or ARC who take AZT for more than several months have needed
repeated transfusions, and there are those who feel that AZT is a highly toxic drug. Since
the data suggest that individuals with lesser degrees of immunocompromise may tolerate
the drug better, some rationale exists for earlier treatment. However, one does not know
whether HIV could become resistant to AZT over long periods of time, since the drug
only suppresses the virus's ability to replicate, and does not kill the virus or remove it
from the body; other chronic viruses (for example, herpes simplex) can develop resistance
to suppressive therapeutic agents.
Other clinical indications for the knowledge of an individual's HIV and immunologic
status are emerging. For example, in children, the use of live virus vaccines, even though
the organisms utilized in the vaccines are avirulent, could result in an HIV-infected im-
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munocompromised child becoming very ill with a disseminated viral infection that the
vaccine was designed to avoid. Family members may be in high-risk groups themselves
and could be susceptible to serious infections from viruses that were excreted by asympto-
matic children who had been recently vaccinated. Thus, the public is left with a fairly
volatile situation, in which no proven interventions have been shown to alter the natural
history ofHIV infection in asymptomatic individuals, though several interventions are on
the horizon. Individuals who are infected with HIV may benefit from knowing about this
if they are going to be exposed to new infectious agents; however, one must be cautionary
in noting that these are theoretical concerns, not ones that are currently standard medical
practice. It is clear that as the medical advances continue— and one can only hope that
they proceed at a rapid pace— then HIV diagnostics will be increasingly more useful.
The test itself will have more meaning for individuals when clinicians have something to
offer them. In the meantime, the public debate about these issues should help to educate
both policymakers and clinicians as to the need to be very clear in their own minds why
they want individuals to be screened for HIV
HIV screening's use as a tool for the modification of high-risk behaviors, and thereby
as a tool to decrease the spread of the retrovirus, is one of the major reasons that policy-
makers have felt the screening should be more widely available. In a context of a program
of intensive education about risk behaviors, HIV testing may be helpful for specific indi-
viduals. Yet it is difficult to generalize about the efficacy of HIV testing itself, since very
few individuals undergo antibody testing without receiving some form of counseling,
which may be more relevant to potential behavior changes.
The substantial changes in high-risk behaviors by the gay and bisexual men in one
Boston study were similar whether individuals were antibody-positive or -negative and
whether or not they knew their test results. 35 On the basis of studies in which individuals
enter as volunteers, are given guarantees of confidentiality, and are not under scrutiny by
public health officials, it is particularly hard to generalize about the effect of mandating
that people know their HIV antibody test results. One can only wonder whether manda-
tory testing could serve merely to intensify the development of an underground that could
be more refractory to the educational messages available in studies, community-based
testing sites, and other institutions that offer the test without coercing individuals to par-
ticipate. The maintenance of a dialogue between the patients and their providers can allow
for mutually reinforcing decisions as to when it is appropriate to perform HIV testing and
what kinds of support the patient will subsequently need in order to maintain safer sexual
practices and to receive appropriate medical follow-up.
Therapeutic Concerns
Another major dilemma for clinicians taking care of individuals with AIDS and HIV
infection relates to the pace of clinical trials. At the present time, most persons with HIV
infection are not receiving medication to counteract the progressive immunocompromise
associated with HIV. Most newly available drugs for treating HIV infection will be tested
in the ATEUs and Clinical Studies Groups (CSGs), which are federally funded and cen-
trally coordinated to perform multicenter clinical trials. A consortium of Harvard Medi-
cal School-affiliated hospitals (Massachusetts General, Beth Israel, New England
Deaconess) is the only such treatment site in New England. The ATEUs have begun sev-
eral protocols utilizing AZT and are planning more studies to look at newer antiretroviral
drugs. Since the criteria for inclusion in a specific clinical study must be fairly rigid, and
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since many individuals may fall between the cracks in terms of the progression of their
specific problems, a large underground has already developed to procure medications
from Mexico and overseas in order to give individuals with AIDS and symptomatic HIV
infection the opportunity to make their own decisions about whether they would want to
receive a specific drug. Of great concern to clinicians is the fact that treatment with the
first two highly publicized agents (Suramin and HPA-23) which act against the HlV-spe-
cific enzyme, reverse transcriptase, turned out to be more toxic than the untreated HIV
infections would have been. Thus, in the absence of meticulous basic research, individ-
uals may become more impressed by the merchandising of purported panaceas and
thereby expose themselves to potential harm. By the same rationale, early HIV testing
may be useful because an individual may be at a better point to take action that can prevent
a more rapid decline in immunologic function. Many clinicians are concerned that drugs
may not be tested soon enough on less symptomatic, seropositive persons. Many asymp-
tomatic individuals, perceiving themselves to be at increased risk for developing sympto-
matic HIV infection in the near future, are clamoring to receive AZT or other, less
studied agents, and they indicate that they do not want to sit and wait while their immuno-
logic function inexorably declines. If many of these minimally symptomatic individuals
had taken HPA-23 or Suramin, they would have caused themselves more harm than bene-
fit. Thus, the federal health authorities feel that in studying new and promising agents,
they must balance the progressively increasing gravity of the epidemic against the need to
conduct studies in a careful and organized fashion.
Many hopes have been raised regarding drugs besides AZT, such as Ribavirin, Ampli-
gen, Phosphonoformate, and a host of other compounds. 36 37 38 Many of these drugs are
now undergoing initial clinical trials, but the process can be a long and arduous one. First,
investigators must develop a hypothesis as to why a specific agent may work in a test tube
and must demonstrate the efficacy of the compound against HIV-infected cells. Initial
studies in humans have to evaluate the pharmacokinetic properties of the drug as well as
its toxicities. Then, studies have to show that in human beings a specific drug may have
efficacy against HIV infection. The traditional investigational gold standard has been to
test a candidate drug in humans against a placebo in a randomized, controlled fashion,
utilizing subjects that are selected to be similar in terms of infection and disease charac-
teristics. Many of the promising reports about agents other than AZT do not involve ran-
domized, controlled trials and thus are often a series of anecdotes. The erratic nature of
HIV infection makes noncontrolled trials difficult to interpret, since some individuals
may remain asymptomatic for as long as nine years after HIV infection, while others may
develop AIDS within a year after seroconversion. Individuals with Kaposi's sarcoma, in
particular, constitute a subgroup that in the absence of opportunistic infections may re-
main quite well, with fairly intact immunologic function, for long periods of time.
The clinical end points that are used to evaluate the efficacy of particular therapies are
still not standardized. If death is utilized as an end point, one has to follow a large cohort
of individuals with fairly advanced HIV infection in order to establish an adequate differ-
ence between a new therapy and a placebo. This was done in the case of the trial of AZT,
but the data in that study indicated that individuals who had ARC tended to benefit more
from AZT than those with AIDS. This would suggest that AZT would be better utilized in
individuals who might have earlier stages of HIV infection. However, the AZT trial in
asymptomatic HIV-seropositive individuals may have to go on for at least three years
before it can be established whether treatment with AZT has a sufficiently large protect-
ive effect to warrant the toxicities that may be encountered in the course of therapy. If one
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does not use death as an end point, but rather opportunistic infections, the cohort size
must still be large and homogeneous at the outset in order to produce meaningful data that
can establish the efficacy of a specific agent. The clinical and laboratory criteria, which
are needed to include individuals in specific cohorts and to assess the effectiveness of
specific agents, have not yet been routinely standardized. For example, some individuals
feel that the presence of thrush is a particularly bad prognostic sign, 39 whereas others are
more concerned by the persistence of constitutional symptoms. It is not clear whether one
can compare an asymptomatic person with thrush to a person who has lost significant
weight and who has persistent fevers, chills, and sweats and multiple hematologic abnor-
malities. In the lab, the most useful immunologic criterion for inclusion in a specific
group that would be evaluated in a drug trial would be the absolute T-helper lymphocyte
number. 40 This has been shown to be useful in epidemiological studies, but whether im-
provement or stabilization in this parameter is the best predictor of chemotherapeutic
efficacy is still an open question. Several virologic parameters may be epidemiologically
useful as well, but further study is required as to their usefulness as prognostic markers
after individuals undergo antiretroviral chemotherapy. Patients who have positive cultures
for HIV or who have been shown to have HIV antigen in their serum (patients may be
antigenemic and not viremic) tend to be more likely to become clinically ill over short
periods of time. 41 42 However, the reversal of antigenemia or the inability to culture virus
after an individual has been treated with a drug may not ipso facto mean that the drug is
highly effective. These parameters are undergoing careful study and will increasingly
become useful in characterizing stages of HIV infection, but the highly individualized
responses to infection with the retrovirus mean that it is still very hard to establish a typol-
ogy that would allow clinicians to give short trials of therapeutic agents and utilize surro-
gate markers as a means for proving drug efficacy. In summary, in the short run there will
be no quick answers as to which drugs are the most effective; rather, ongoing studies of
natural history will be necessary, unless novel agents are developed which prove to be
highly effective in altering or reversing the HIV-induced immunodeficiency and its se-
quelae.
The need for long-term, prospective, careful studies of individuals, utilizing placebos
and careful controls, is clear-cut. Yet, given the magnitude of human suffering engen-
dered by HIV infection, many clinicians feel that an academic approach is unacceptable.
Some individuals have felt that historical controls can be used to establish baseline rates of
progression in the natural history of HIV infection and that these can be compared to
individuals who are treated with specific regimens. The problem with using historical
controls is that as the epidemic evolves, there are changes in the natural history of HIV
infection which have been unanticipated. Thus, comparisons of people who were infected
with HIV several years ago with those who are undergoing therapeutic regimens now may
lead to skewed interpretations. For example, at the outset of the epidemic, almost one-
third of individuals who were initially diagnosed using the CDC definition of AIDS had
Kaposi's sarcoma, whereas at the present time less than one-fifth of the new cases carry
this diagnosis. It is unknown whether the decreased incidence of Kaposi's sarcoma re-
flects changes in behavior, changes in certain biological cofactors (such as the use of
volatile nitrites, or "poppers"), or decreased transmission of another viral cofactor.
The vagaries of the natural history of HIV have complicated the need for expeditious
clinical trials, and appropriate clinical concerns have been perceived by some segments of
the population as an insensitivity. This has led to the burgeoning of the therapeutic under-
ground and to an increased alienation from clinical investigators among some HlV-in-
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fected persons. Occasionally, individuals who have participated in randomized trials have
gone so far as to utilize drug-analysis laboratories in order to assess whether they are
receiving a placebo, and have either dropped out of trials or have supplemented their regi-
mens with nonprotocol drugs because of their sense of urgency regarding treatment.
These anecdotes reflect the exceptions rather than the rule, but they underscore the highly
charged environment that is evolving in this time of uncertainty. Individual self-medica-
tion has the potential to create serious therapeutic problems, since if every individual who
were HIV-infected were to experiment with different types of drugs, the results that might
be obtained in specific clinical trials would be difficult to interpret. But many seropositive
persons are uncomfortable not knowing whether they have received a placebo. The in-
creased availability ofAZT and the lack of a standard, accepted criterion by all clinicians
in prescribing the drug create the potential to exacerbate this situation further. At the
present time, it is known only that individuals who have had one episode ofPneumo-
cystis carinii pneumonia or who have constitutional symptoms and other ARC-like mani-
festations have had their lives extended by taking AZT. However, many HIV-infected
individuals who have either minor opportunistic infections, such as thrush or zoster, or
asymptomatic depressions in their T-helper lymphocyte count, or both, are electing to
take AZT. In the absence of clear-cut data and through the process of extrapolating from
the clinical trials of sicker individuals, they prefer risking the potential toxicities ofAZT
to waiting until it is clearly shown that taking the drug at earlier stages of infection is use-
ful. Blanket statements saying that individuals must either be in clinical trials or not take
medication are not realistic in the current climate. On the other hand, if everybody did
exactly as they pleased, utilizing any available drugs through the black market, further
knowledge about the efficacy of antriretroviral therapy could be critically delayed or
limited. There are no easy or glib answers. An ongoing dialogue among researchers,
clinical providers, and the communities at risk for HIV infection must continue, in order
to address these highly urgent human needs in a responsible fashion. Yet an adequate level
of scientific rigor must also be maintained so that these crucial questions can be answered
as rapidly as possible.
Up until now, clinical trials have tended to look for the magic bullet, that is, a single
drug that will attenuate the effects of HIV infection. However, many researchers feel that
this approach may be simplistic, since the individual with HIV infection faces two types of
problems. Because the virus is immunosuppressive, the individual must have his or her
immune system restored if the onset of opportunistic infections or malignancy is to be
avoided. At the same time, the retrovirus itself must be inhibited from replicating in order
to prevent the extension of the infection and subsequent further immunosuppression. 43 44
Some of the first drugs to treat HIV infection were stimulators of the immune system,
such as interferon and interleukin-2. 45 Whereas they tended to increase the numbers of
lymphocytes which could potentially fight infection, they also tended to enhance the abil-
ity of HIV to replicate, thus abetting infection, and were ultimately not successful by
themselves. Drugs like AZT inhibit specific enzymes of the virus and prevent it from
multiplying, but do not restore the immune system by themselves. Thus, the possibility
exists that combined chemotherapy with an immunostimulatory drug and a drug that acts
specifically against the virus could be a major answer in treating individuals with HIV
infection and preventing further immunologic compromise. 46 However, in order to assess
adequately the potential toxicities of individual agents, such trials would have to be per-
formed serially; in other words, the effects of either drug by itself would first have to be
assessed, and only then could the drugs be studied in combination. Thus, some ap-
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proaches offer much promise, but even more time may be required to study them in a
responsible fashion, thus further straining the patience of individuals who are at risk for
immunologic compromise. Some feel that although serial trials of these drugs represent a
scientifically worthwhile approach, so many individuals could clinically deteriorate be-
fore definite data were collected that combination studies should begin in a more expedi-
tious fashion. Previous medical experience shows, however, that when two drugs are
given together, unexpected synergistic toxicities supervene instead of synergistic thera-
peutic effects. Dual therapy may result in lessened therapeutic efficacy of either drug
alone (antagonism) in vivo even if in vitro data look promising. Thus, the dialogue be-
tween the affected individuals and the research community must take each side into ac-
count. The old dictum, Primum non noce (First do no harm), must be balanced against
the problem that can result from too much delay in initiating a promising therapeutic
regimen. The only answer is constant questioning and dialogue in order to expedite the
process of making useful combination treatments available, without rushing to judgment
in such a way that more individuals are harmed because of inadequate antecedent study.
Care-Related Issues
The AIDS epidemic raises many issues regarding the optimal delivery of services to indi-
viduals infected with HIV who subsequently develop problems related to immunocom-
promise. Although persons with AIDS have a markedly shortened life expectancy, they
can respond well to specific treatment regimens, particularly after their first episodes of
opportunistic infection. The initial approach toward the management of patients with HIV
infection tended to be technologically intensive, and led to patients being hospitalized for
longer periods of time. The model developed in San Francisco is one that optimally uti-
lizes outpatient resources and maximizes home care and treatment in the ambulatory
setting. Unfortunately, the ways in which health care is financed in many areas tend to
create disincentives for early discharge and the provision of comprehensive outpatient
services. This will become increasingly penny-wise and pound-foolish, given the avail-
ability of prophylactic regimens that require some level of medical expertise, such as the
administration of aerosolized Pentamidine in order to prevent the recurrence of Pneumo-
cystis carinii pneumonia. Health care planners and policymakers will need to continually
talk to clinicians, patients, and advocacy groups for individuals at high risk for HIV infec-
tion in order to create the most satisfactory approaches to caring for individuals in com-
munity settings, which may provide a less depressing environment and which certainly
provide a less costly one. In order for these novel programs to be successful, there must
be a comprehensive set of supports which includes a wide range of health care providers,
including home health aides, nursing assistants, physical and occupational rehabilitation
specialists, nutritionists, and mental-health-care workers, so that the deinstitutionalized
patients do not return to tertiary institutions with more complicated medical problems that
could have been anticipated had the appropriate interventions been instituted earlier.
Health care providers such as physicians and nurses need to increasingly become aware
that many of the individuals at highest risk for HIV infection do not come from "tradi-
tional" social environments. The effectiveness of the health care team can only be en-
hanced if providers recognize the validity of same-sex spouses, nonnuclear family units,
and nonmedical resources in communities that comprise sexual, cultural, and racial mi-
norities. Since so much of HIV infection relates to behavioral issues, providers must
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educate themselves about alternative lifestyles and must understand how critical it is that
they relate to clients as nonjudgmental care givers and educators.
HIV infection results in problems that involve the whole patient, who is the sum total of
many parts greater than individual subspeciality concerns. Therefore, patients who are
infected with the retrovirus need to be approached clinically by a multidisciplinary team
of health care providers. This team must include subspecialists in areas of expertise such
as infectious diseases, hematology, oncology, pulmonary diseases, gastroenterology, and
often a host of other subspecialities. However, these patients have a great need to have
their care integrated; thus, there will be a continuing need for primary care generalists to
serve as their gateway to the health care system. In some university hospital settings,
infectious disease specialists tend to be the primary providers of care for individuals with
symptomatic HIV infection, but in others, general internists and family practitioners have
done a fine job and have tended to be the health care providers who oversee the series of
consultations that may be necessary in the course of HIV infection for any given individ-
ual. The health care team can be greatly enhanced by the inclusion of nurse practitioners
and physicians' assistants who have developed specific skills around AIDS and HIV infec-
tion, since individuals with these problems may need a great deal of education, moral
support, and clinical monitoring that do not necessitate the constant involvement of the
subspecialist. In addition, the ongoing involvement of mental health professionals ranging
from neurologists to social workers can greatly enhance the ability of individuals with
HIV infection to function well in society. Not every individual with HIV infection will
invariably need to see the psychiatrist or the gastroenterologist, but it is important to de-
velop a referral network that will allow for a rational pattern of integrated health care for
each individual who is diagnosed with HIV infection and its attendant clinical sequelae.
Infection Control
The last major policy issue regarding HIV infection relates to infection control. As with
so many other aspects of the AIDS epidemic, the public dialogue on this issue has tended
to careen between hysteria and apathy, whereas the most appropriate course is one of
prudent caution based on the well-documented epidemiology of retroviral infection. The
precautions that providers need to take regarding HIV infection are virtually identical to
those which are taken with respect to any bloodborne disease and have been recently well
described by the Centers for Disease Control. 47 One must add the caveat that individuals
who are infected with HIV may be more susceptible to certain types of infections — for
example, tuberculosis — that may in and of themselves be contagious to individuals with
intact immune systems. Therefore, clinicians need to respond with the appropriate
thoughtful caution in the care of individuals with HIV infection. Thus, if an individual
who has HIV infection has an atypical chest x-ray and is coughing, it behooves the provi-
der to suggest that the patient be placed on respiratory isolation until the diagnosis of
tuberculosis is excluded. However, irrational infection control procedures serve only to
stigmatize the individual, give a false sense of security to staff members, and lead to sub-
optimal, alienated medical care.
Traditional practice has included the documentation in the medical record of all infor-
mation that could possibly be of clinical importance, on the presumption that no clini-
cian's memory is infallible and that others may benefit from this documentation in the
future. However, antidiscrimination provisions against individuals with HIV infection
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are lacking in most jurisdictions, and since, particularly in small medical settings, it is
very difficult to keep medical information inviolate, individuals may be at risk from ex-
ternal social sanction if their HIV status is documented. Therefore, many have felt that
information about persons with HIV infection should never be placed in the medical rec-
cord. However, where HIV-related information has been obtained in a noncoercive fash-
ion and where knowledge of this information on the part of other members of the health
care team may be important for patient management, it seems that discussion should focus
not on the compromise of medical care, but on how best to protect individuals from capri-
cious or inappropriate disclosure and subsequent discrimination. Therapeutic interven-
tions available for HIV-infected individuals, it is hoped, will continue to increase over the
next few years, and as they do, the likelihood will also grow that within the health care
system more individuals will be disclosed as HIV-infected. In order to avoid further exac-
erbation of the patients' need for comprehensive medical care, which may necessitate
documentation of their clinical status, legislation that addresses the just concerns of pa-
tients is urgently needed. Discussions among medical providers, those who make public
policy, and the general public must lead to a resolution that creates an environment in
which individuals will not be stigmatized in the process of seeking health care.
With more than one million HIV-infected persons in the United States, any actions that
potentiate alienation from the health care system and impede education around risk reduc-
tion are inappropriate. In the midst of this distressing epidemic, all of us — researchers,
providers, patients, and the public — face the great challenge of having to rapidly assimi-
late new technical information while remodeling the anachronistic social systems that tend
to increase the underlying anxieties. Until we have definitive therapeutics and chemopro-
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Glossary continuedfrom page 36
Alterations in immune function which are suggestive of a
decreased ability to fight off infections and the development
of malignancies.
The processes by which the body is able to prevent im-
munocompromise.
The process by which substances turn on specific parts of
the immune system.
Experiments that occur in artificial laboratory environ-
ments outside the living body.
Experiments that occur in the living organism, either using
animal models or clinical studies that take place in humans.
A rash that is reddened, with some irregular raised surfaces.
Any process that results in an alteration of the nervous
system. This can result in confusion, coma, muscle weak-
ness, strange sensations, or any combination of these.
Any process that impairs the functioning of specific nerves.
Infectious diseases or tumors that develop because of a
weakening of the immune system, so that processes which
are usually quite innocuous take advantage of the resultant
immunocompromised state.
Swollen glands in more than one noncontiguous site through-
out the body which stay enlarged for at least three months.
Any combination that results in a multiplicative effect




A type of white blood cell that is responsible for orchestrat-
ing many of the interactions of different, other blood cells
in the immune system. This is one of the cell types that
become particularly affected by HIV, and the T-helper
lymphocyte count can be a useful marker in following the
progress of HIV infection in specific individuals.
A yeast infection of the tongue.
Reactivation of the chicken pox virus, also known as shin-
gles. This usually results in a painful band either on the
trunk or on the face, with painful blisters.
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"I don 't consider myselfa person who 's dyingfrom AIDS. I
certainly consider myselfa person who s been living with AIDS.
I don 't consider myselfan AIDS victim, and I really wish people
in the media would stop using that terminology. I think that's one
ofthe most damning things that you can say about a person, is
that they 'rejust a victim, and I think thatpart ofthe way I've
come to look at this is that I'm a person who 's still in control of
my life and I refuse to be victimized by AIDS or anyone who 's
connected with this disease in any way. I maintain control.
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Yeastlike fungus infection of the esophagus.
Viral infection whereby a small virus attacks the liver, often
producing jaundice.





Persistent inflammation of the lymph nodes, particularly
the axilla and groin, in response to an infection.
Transmission of the virus from the bloodstream of the
mother to the blood of the unborn baby.
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